Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny s...
Alzamend Neuro, Inc. (Nasdaq:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”),...
Alzamend Neuro ( NASDAQ: ALZN ) said on Monday it had received a written response to its meeting request relating to its Type B Pre-Investigational New Drug application from the U.S. Food and Drug Administration. The company said the FDA’s response provides a pa...
Topline data expected in December 2022 from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s Full data from Phase I first-in-human study demonstrated AL001 in plasma is bioequivalent to the marketed lithium ...
Company to report on progress with clinical trials of AL001 and upcoming IND submission for AL002 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the trea...
Drug developer Alzamend Neuro (NASDAQ:ALZN) said on Tuesday it had submitted a Pre-IND (investigational new drug) meeting request to the U.S. Food and Drug Administration for its drug, AL001, to treat bipolar disorder, major depressive disorder and post-traumatic stress disorder. ALZN st...
Topline data expected in December 2022 from ongoing Phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer’s Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopha...
Check These 3 Penny Stocks Out For Your Watchlist As we end another week of trading penny stocks and blue chips, there is a lot for investors to keep in mind. Despite mostly positive sentiment as the week ended, penny stocks and blue chips have been in a blood bath in the past few m...
Topline data expected in December 2022 Full data from Phase I first-in-human study demonstrated AL001 in plasma is bioequivalent to the marketed lithium carbonate product Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early c...
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“ DP Lending ”) has made an additional investme...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...